Multiple system atrophy
Therapeutic area
Neurology
Rare disease
Yes
- Definition
- Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by autonomic failure (cardiovascular and/or urinary), parkinsonism, cerebellar impairment and corticospinal signs with a median survival of 6-9 years.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Multiple system atrophy
- Therapeutic area
- Neurology
- multiple system atrophy
- MSA
- Shy-Drager syndrome
- multisystem atrophy
- Shy-dragger syndrome (formerly)
- Severity
- Severe
- Metabolic Disease
- Neurology
- MONDO ID
- MONDO:0007803
- Parent condition
- MONDO:0000510
Related records
Broader conditions (12)
- Central nervous system disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by molecular mechanism
- Human disease
- Metabolic disease
- Movement disorder
- Nervous system disorder
- Neurodegenerative disease
- Proteostasis deficiencies
- Synucleinopathy
Narrower conditions (10)
- Autosomal dominant striatal neurodegeneration type 1
- Familial infantile bilateral striatal necrosis
- Multiple system atrophy, cerebellar type
- Multiple system atrophy, parkinsonian type
- Pure autonomic failure
- Striatal degeneration, autosomal dominant
- Striatal degeneration, autosomal dominant 2
- Striatonigral degeneration
- Striatonigral degeneration, childhood-onset
- Striatonigral degeneration, infantile, mitochondrial
Trials (223)
- "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
- [18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients
- [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
- [18F]ACI-15916 PET in α-synucleinopathies
- [18F]F-DOPA Imaging in Patients With Autonomic Failure
- A Biomarker Study of ATH434 in Participants With MSA
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
- A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)
- A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects
- A Futility Trial of Sirolimus in Multiple System Atrophy
- A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
- A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
- A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
- A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With Synucleinopathies
- A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy
- A Study of Lu AF82422 in Participants With Multiple System Atrophy
- A Study of TAK-341 in Treatment of Multiple System Atrophy
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
- A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA
- A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
Approved drugs (2)
- Droxidopa
- Ioflupane I 123
Drugs in development (20)
- Amlenetug Phase 2
- Ampreloxetine Phase 3
- Epigalocatechin gallate Phase 3
- Exenatide Phase 2
- Fluoxetine Phase 2
- Foralumab Phase 2
- Human immunoglobulin G Phase 2
- Indenebart Phase 2
- Inosine Phase 2
- Insulin human Phase 2
- Lithium carbonate Phase 2
- PBT-434 Phase 2
- Pseudoephedrine Early phase 1
- Rasagiline mesylate Phase 2
- Rifampin Phase 3
- Riluzole Phase 3
- Safinamide Phase 2
- Sirolimus Phase 2
- Sodium chloride Phase 2
- Verdiperstat Phase 3